Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1979 2
1980 2
1981 1
1982 1
1983 2
1985 2
1988 2
1989 1
1992 1
1993 2
1994 1
1995 2
1996 1
1997 2
1998 2
1999 2
2000 5
2001 5
2002 6
2003 1
2004 5
2005 4
2006 4
2007 2
2008 5
2009 11
2010 10
2011 7
2012 6
2013 7
2014 10
2015 7
2016 8
2017 6
2018 11
2019 6
2020 9
2021 8
2022 6
2023 6
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Results by year

Filters applied: . Clear all
Page 1
Uterine sarcomas.
Mbatani N, Olawaiye AB, Prat J. Mbatani N, et al. Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:51-58. doi: 10.1002/ijgo.12613. Int J Gynaecol Obstet. 2018. PMID: 30306577
The prognosis for carcinosarcomas (which are considered here in a postscript fashion) is usually worse than that for grade 3 endometrial carcinomas. Tumor stage is the single most important prognostic factor for uterine sarcomas....
The prognosis for carcinosarcomas (which are considered here in a postscript fashion) is usually worse than that for grade 3 endometr …
Uterine Adenosarcoma.
Ulrich UA, Denschlag D. Ulrich UA, et al. Oncol Res Treat. 2018;41(11):693-696. doi: 10.1159/000494067. Epub 2018 Oct 17. Oncol Res Treat. 2018. PMID: 30326467 Review.
Adenosarcomas stage I without sarcomatous overgrowth have a rather good prognosis, with a 5-year overall survival up to 80%. For treatment, complete surgical removal is advocated. ...
Adenosarcomas stage I without sarcomatous overgrowth have a rather good prognosis, with a 5-year overall survival up to 80%. For trea …
Endometriosis-associated ovarian neoplasia.
Matias-Guiu X, Stewart CJR. Matias-Guiu X, et al. Pathology. 2018 Feb;50(2):190-204. doi: 10.1016/j.pathol.2017.10.006. Epub 2017 Dec 11. Pathology. 2018. PMID: 29241974 Review.
However, high-stage tumours, particularly clear cell carcinomas, generally have a poor prognosis and this partly reflects relative resistance to current treatment. ...
However, high-stage tumours, particularly clear cell carcinomas, generally have a poor prognosis and this partly reflects relative re …
Prognostic factors in patients with uterine sarcoma: the SARCUT study.
Zapardiel I, Gracia Segovia M, Macuks R, Mancari R, Achimas-Cadariu P, Corrado G, Bartusevicius A, Sukhin V, Muruzabal JC, Coronado Martín PJ, Gardella B, Piek JM, Concin N, Arab C, Papatheodorou D, Polterauer S, Iacoponi S, Nieto T, Lopez-Sanclemente MC, Trukhan H, Gil MM, Bakinovskaya I, Dalamanava A, Cucurull M, Rovski D, Baquedano L, Chiva L, Mardas M, Mavrichev SA, Klat J, Lopez de la Manzanara CA, Yildirim Y; SARCUT Study Group. Zapardiel I, et al. Int J Gynecol Cancer. 2023 Jun 5;33(6):897-904. doi: 10.1136/ijgc-2022-004204. Int J Gynecol Cancer. 2023. PMID: 37192761
The aim of this study was to identify and evaluate the impact of the different prognostic factors on overall survival and disease-free survival of patients with uterine sarcoma. ...CONCLUSION: Incomplete cytoreduction, tumor persistence, advanced stage, extra-uterine and t …
The aim of this study was to identify and evaluate the impact of the different prognostic factors on overall survival and disease-fre …
Uterine Adenosarcoma.
Pinto A, Howitt B. Pinto A, et al. Arch Pathol Lab Med. 2016 Mar;140(3):286-90. doi: 10.5858/arpa.2014-0523-RS. Arch Pathol Lab Med. 2016. PMID: 26927725 Free article.
In all cases, it is important to assess for the presence of sarcomatous overgrowth and myometrial invasion, which are the prognostic factors. In this brief review, we present the clinical, histopathologic, and immunohistochemical features of adenosarcoma, as well as update …
In all cases, it is important to assess for the presence of sarcomatous overgrowth and myometrial invasion, which are the prognostic …
Uterine Adenosarcoma: a Review.
Nathenson MJ, Ravi V, Fleming N, Wang WL, Conley A. Nathenson MJ, et al. Curr Oncol Rep. 2016 Nov;18(11):68. doi: 10.1007/s11912-016-0552-7. Curr Oncol Rep. 2016. PMID: 27718181 Review.
Management of sarcomas of the uterus.
Novetsky AP, Powell MA. Novetsky AP, et al. Curr Opin Oncol. 2013 Sep;25(5):546-52. doi: 10.1097/CCO.0b013e328363e0ef. Curr Opin Oncol. 2013. PMID: 23942299 Review.
PURPOSE OF REVIEW: Uterine sarcomas are rare malignancies accounting for 8-10% of all uterine malignancies, but are significantly more aggressive and have worse prognosis. Management of uterine sarcomas including leiomyosarcoma (LMS), endometrial stromal sarcoma, high-grad …
PURPOSE OF REVIEW: Uterine sarcomas are rare malignancies accounting for 8-10% of all uterine malignancies, but are significantly more aggre …
Clinical characteristics and prognosis analysis of uterine sarcoma: a single-institution retrospective study.
Wang F, Dai X, Chen H, Hu X, Wang Y. Wang F, et al. BMC Cancer. 2022 Oct 7;22(1):1050. doi: 10.1186/s12885-022-10129-x. BMC Cancer. 2022. PMID: 36207687 Free PMC article. Review.
BACKGROUND: Uterine sarcomas are rare and aggressive gynaecologic malignancies, characterized by a relatively high recurrence rate and poor prognosis. The aim of this study was to investigate the clinicopathological features and explore the prognostic factors of the …
BACKGROUND: Uterine sarcomas are rare and aggressive gynaecologic malignancies, characterized by a relatively high recurrence rate and poor …
Endometrial pathology.
Czernobilsky B, Lifschitz-Mercer B. Czernobilsky B, et al. Curr Opin Obstet Gynecol. 1997 Feb;9(1):52-6. Curr Opin Obstet Gynecol. 1997. PMID: 9090483 Review.
Prognostic factors for uterine adenosarcoma: a review.
Nathenson MJ, Conley AP. Nathenson MJ, et al. Expert Rev Anticancer Ther. 2018 Nov;18(11):1093-1100. doi: 10.1080/14737140.2018.1518136. Epub 2018 Sep 11. Expert Rev Anticancer Ther. 2018. PMID: 30169984 Review.
In fact, at least 50% of patients will develop disease recurrence. Establishing prognostic factors is of paramount importance. Areas covered: This article reviews the current literature regarding adenosarcoma prognostic factors from case reports, case series, and re …
In fact, at least 50% of patients will develop disease recurrence. Establishing prognostic factors is of paramount importance. Areas …
165 results